Jun 11, 2020
Medicenna to Present at Raymond James Human Healthcare Innovation Conference
May 29, 2020
Medicenna Presents Data on MDNA11, an IL-2 Superkine at ASCO 2020
May 29, 2020
Medicenna Updates Efficacy Results from Phase 2b Recurrent GBM Trial at ASCO 2020
May 15, 2020
Medicenna Announces March 31, 2020 Year-End Results
May 04, 2020
Medicenna Announces Upcoming Presentations at the ASCO Annual Meeting
Mar 25, 2020
Medicenna's IL-2 Superkine, MDNA19, Demonstrates Best-in-Class Features in a Non-Human Primate Study
Feb 13, 2020
Medicenna Reports Third Quarter Fiscal 2020 Financial Results
Jan 13, 2020
Medicenna Reports Compelling Results from Recurrent Glioblastoma Trial When Compared to an Eligibility-Matched Control Arm
Jan 08, 2020
Medicenna Receives $1.3 Million Through Early Warrant Exercises
Dec 12, 2019
Medicenna Presents Additional Encouraging Phase 2b Clinical Data at the Inaugural Glioblastoma Drug Development Annual Summit
Dec 09, 2019
Medicenna Announces Presentation of the MDNA55 Clinical Trial at the Inaugural Glioblastoma Drug Development Annual Summit
Nov 25, 2019
Medicenna Reports Promising Efficacy in Phase 2b MDNA55 Clinical Trial at the Society for Neuro-Oncology Annual Meeting
Nov 21, 2019
Medicenna Reports Improved Drug Distribution of MDNA55 with Novel Delivery Technology in Phase 2b Recurrent Glioblastoma Clinical Trial
Nov 20, 2019
Medicenna To Host Key Opinion Leader Call Focused on Latest MDNA55 Recurrent Glioblastoma Phase 2b Clinical Study Results
Nov 18, 2019
Medicenna to Host a Key Opinion Leader Symposium on MDNA55 for Treatment of Recurrent Glioblastoma
Nov 14, 2019
Medicenna Announces Presentations on MDNA55 Recurrent Glioblastoma Clinical Trial at the Annual Meeting of the Society of Neuro-Oncology
Sep 30, 2019
Medicenna Presented Promising Preclinical Results from its IL-2 Superkine Platform at the 5th Annual International Cancer Immunotherapy Conference
Sep 26, 2019
Nature Communications Publishes Studies on Medicenna's IL-2 Superkine Platform
Sep 25, 2019
Medicenna Presents Promising Update from its MDNA55 Clinical Trial in Recurrent Glioblastoma at the Targeting Innate Immunity Congress
Sep 24, 2019
Medicenna Strengthens Board of Directors by Appointment of Seasoned Biopharma Executive Ms. Karen Dawes